DE60129278D1 - Gegen das SEMP1-Protein gerichtete Antikörper, Verfahren zu deren Herstellung, und deren Anwendungen - Google Patents
Gegen das SEMP1-Protein gerichtete Antikörper, Verfahren zu deren Herstellung, und deren AnwendungenInfo
- Publication number
- DE60129278D1 DE60129278D1 DE60129278T DE60129278T DE60129278D1 DE 60129278 D1 DE60129278 D1 DE 60129278D1 DE 60129278 T DE60129278 T DE 60129278T DE 60129278 T DE60129278 T DE 60129278T DE 60129278 D1 DE60129278 D1 DE 60129278D1
- Authority
- DE
- Germany
- Prior art keywords
- semp1
- dsm
- protein
- preparation
- directed against
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
- C12N2799/026—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a baculovirus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
- C12N2799/027—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a retrovirus
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Ophthalmology & Optometry (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP00113344A EP1167387A1 (de) | 2000-06-23 | 2000-06-23 | Anti-SEMP1-Antikörper, Verfahren zu deren Herstellung, und deren Anwendungen |
EP00113344 | 2000-06-23 | ||
EP01107799 | 2001-04-05 | ||
EP01107799 | 2001-04-05 |
Publications (2)
Publication Number | Publication Date |
---|---|
DE60129278D1 true DE60129278D1 (de) | 2007-08-23 |
DE60129278T2 DE60129278T2 (de) | 2008-03-20 |
Family
ID=26071070
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE60129278T Expired - Lifetime DE60129278T2 (de) | 2000-06-23 | 2001-06-22 | Gegen das SEMP1-Protein gerichtete Antikörper, Verfahren zu deren Herstellung, und deren Anwendungen |
Country Status (10)
Country | Link |
---|---|
US (1) | US6627439B2 (de) |
EP (1) | EP1167389B1 (de) |
JP (1) | JP3542784B2 (de) |
AT (1) | ATE366746T1 (de) |
AU (1) | AU750296B2 (de) |
CA (1) | CA2348026C (de) |
DE (1) | DE60129278T2 (de) |
DK (1) | DK1167389T3 (de) |
ES (1) | ES2290072T3 (de) |
PT (1) | PT1167389E (de) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040033228A1 (en) | 2002-08-16 | 2004-02-19 | Hans-Juergen Krause | Formulation of human antibodies for treating TNF-alpha associated disorders |
CA2496272A1 (en) * | 2002-08-20 | 2004-03-04 | Millennium Pharmaceuticals, Inc. | Integrin b6 markers for compositions, kits, and methods for identification, assessment, prevention and therapy of cervical cancer |
EP2016100B1 (de) * | 2006-05-04 | 2014-07-09 | The Rockefeller University | Hcv-corezeptor und verfahren zu seiner anwendung |
ES2529511T3 (es) * | 2008-09-25 | 2015-02-20 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Anticuerpos monoclonales anti-claudina 1 para la inhibición de la infección por virus de la hepatitis C |
CN103429265A (zh) | 2010-05-25 | 2013-12-04 | 国家医疗保健研究所 | 用于治疗和预防hcv感染的抗包膜抗体和抗受体抗体组合物 |
WO2013024156A2 (en) | 2011-08-17 | 2013-02-21 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Combinations of anti-hcv-entry factor antibodies and interferons for the treatment and the prevention of hcv infection |
WO2013024155A1 (en) | 2011-08-17 | 2013-02-21 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Combinations of anti-hcv-entry factor antibodies and direct acting antivirals for the treatment and the prevention of hcv infection |
WO2013024157A2 (en) | 2011-08-17 | 2013-02-21 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Combinations of host targeting agents for the treatment and the prevention of hcv infection |
JP6393875B2 (ja) * | 2013-02-28 | 2018-09-26 | 公益財団法人ヒューマンサイエンス振興財団 | 抗体 |
JP2016528221A (ja) * | 2013-08-02 | 2016-09-15 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | 抗クローディン1抗体およびその使用 |
WO2015014657A1 (en) * | 2013-08-02 | 2015-02-05 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Anti-claudin 1 antibodies for use in the treatment of colorectal cancer |
EP3070103A1 (de) | 2015-03-19 | 2016-09-21 | Institut Hospitalier Universitaire De Strasbourg | Monoklonale anti-claudin 1-antikörper zur vorbeugung und behandlung von hepatozellulärem karzinom |
EP3821946A1 (de) | 2019-11-12 | 2021-05-19 | Université de Strasbourg | Monoklonale anti-claudin-1-antikörper zur prävention und behandlung von fibrotischen erkrankungen |
CN113455494A (zh) * | 2021-05-12 | 2021-10-01 | 南京生航生物技术有限公司 | 一种无血清细胞冻存液及制备方法和制备装置 |
WO2023170606A1 (en) | 2022-03-08 | 2023-09-14 | Alentis Therapeutics Ag | Use of anti-claudin-1 antibodies to increase t cell availability |
WO2023233364A1 (en) | 2022-06-01 | 2023-12-07 | Alentis Therapeutics Ag | Use of anti-claudin-1 antibodies to treat cholangiocarcinoma |
WO2023233363A1 (en) | 2022-06-01 | 2023-12-07 | Alentis Therapeutics Ag | Use of anti-claudin-1 antibodies to treat cholangiopathies |
WO2024069009A1 (en) | 2022-09-30 | 2024-04-04 | Alentis Therapeutics Ag | Treatment of drug-resistant hepatocellular carcinoma |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2299226A1 (en) | 1997-08-06 | 1999-02-18 | Millennium Biotherapeutics, Inc. | Tango-71, tango-73, tango-74, tango-76, and tango-83 nucleic acid molecules and polypeptides |
AU8693598A (en) | 1997-08-08 | 1999-03-01 | University Of Washington | Isolation of a novel senescence-factor gene, p23 |
JP2002519029A (ja) | 1998-06-29 | 2002-07-02 | インサイト・ファーマスーティカルズ・インコーポレイテッド | アポトーシス関連分子 |
-
2001
- 2001-05-31 AU AU50079/01A patent/AU750296B2/en not_active Ceased
- 2001-06-08 CA CA002348026A patent/CA2348026C/en not_active Expired - Fee Related
- 2001-06-21 US US09/886,683 patent/US6627439B2/en not_active Expired - Fee Related
- 2001-06-22 EP EP01114743A patent/EP1167389B1/de not_active Expired - Lifetime
- 2001-06-22 ES ES01114743T patent/ES2290072T3/es not_active Expired - Lifetime
- 2001-06-22 PT PT01114743T patent/PT1167389E/pt unknown
- 2001-06-22 DK DK01114743T patent/DK1167389T3/da active
- 2001-06-22 AT AT01114743T patent/ATE366746T1/de active
- 2001-06-22 DE DE60129278T patent/DE60129278T2/de not_active Expired - Lifetime
- 2001-06-25 JP JP2001191790A patent/JP3542784B2/ja not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
CA2348026A1 (en) | 2001-12-23 |
JP2002332300A (ja) | 2002-11-22 |
ES2290072T3 (es) | 2008-02-16 |
CA2348026C (en) | 2005-06-07 |
EP1167389A1 (de) | 2002-01-02 |
ATE366746T1 (de) | 2007-08-15 |
AU750296B2 (en) | 2002-07-11 |
EP1167389B1 (de) | 2007-07-11 |
US20020150574A1 (en) | 2002-10-17 |
JP3542784B2 (ja) | 2004-07-14 |
US6627439B2 (en) | 2003-09-30 |
PT1167389E (pt) | 2007-09-27 |
DK1167389T3 (da) | 2007-11-12 |
DE60129278T2 (de) | 2008-03-20 |
AU5007901A (en) | 2002-01-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE60129278D1 (de) | Gegen das SEMP1-Protein gerichtete Antikörper, Verfahren zu deren Herstellung, und deren Anwendungen | |
DE69724428D1 (de) | Humanisierte antikörper die an das gleiche antigen wie antikörper nr-lu-13 binden und deren verwendung in "pretargeting" verfahren | |
CY1118443T1 (el) | Anti-tnf αντισωματα, συνθεσεις, μεθοδοι και χρησεις | |
ATE470714T1 (de) | Antikörper gegen doppelintegrinen, zusammensetzungen, verfahren und verwendungen | |
ATE384792T1 (de) | Antikörpervarianten mit höheren bindungsaffinitäten im vergleich zu parentalen antikörpern | |
CY1108545T1 (el) | Πρωτεϊνες υπομοναδας υποδοχεα κυτοκινης θηλαστικου, σχετικα αντιδραστηρια και μεθοδοι | |
CA2469833A1 (en) | Canine immunoglobulin variable domains, caninized antibodies, and methods for making and using them | |
ATE461938T1 (de) | Mit entzündlichen darmerkrankungen (ibd) assoziierte mikrobielle antigene und verfahren derer anwendung | |
DE60235588D1 (de) | Monoklonales Antikörper gegen das HCV Kernantigen | |
ATE395364T1 (de) | Gegen procalcitonin gerichtete antikörper, ihre herstellung und verwendung | |
EP1908837A3 (de) | Menschliche Rezeptorproteine, zugehörige Reagenzien und Verfahren | |
GB2278357B (en) | Humanised antibodies directed against A33 antigen | |
ATE353335T1 (de) | Einkettige antikörper gegen eine p53 mutante | |
EP1230932A3 (de) | Verwendung von Antikörpern zur Vakzinierung gegen Krebs | |
TR200102877T2 (tr) | İmmünoglobulinin kendi yüksek afinite reseptörüne bağlanmasını inhibe eden antikorlara karşı anti-idiotipik antikorlar. | |
DE60128452D1 (de) | Monoklonale antikörper gegen den menschlichen ldl-rezeptor, deren herstellung und verwendung | |
ATE131069T1 (de) | Composition comprising at least two different antibodies or fragments thereof. | |
TH84976B (th) | วิธีการวินิจฉัยการติดเชื้อด้วยโคโรนาไวรัส ต้นเหตุของโรคซาส์ (sars) | |
BR0204612A (pt) | Anticorpos monoclonais antinúcleo de hcv | |
BR1100582B1 (pt) | famÍlia de anticorpos modificados, de alta afinidade, para tratamento de cÂncer. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8363 | Opposition against the patent |